| Literature DB >> 29403423 |
Stefan Kammermeier1, Lucia Dietrich1,2, Kathrin Maierbeck1,3, Annika Plate1, Stefan Lorenzl1,4, Arun Singh1,5, Ahmad Ahmadi1, Kai Bötzel1.
Abstract
Progressive supranuclear palsy (PSP) and late-stage idiopathic Parkinson's disease (IPD) are neurodegenerative movement disorders resulting in different postural instability and falling symptoms. IPD falls occur usually forward in late stage, whereas PSP falls happen in early stages, mostly backward, unprovoked, and with high morbidity. Self-triggered, weighted movements appear to provoke falls in IPD, but not in PSP. Repeated self-triggered lifting of a 0.5-1-kg weight (<2% of body weight) with the dominant hand was performed in 17 PSP, 15 IPD with falling history, and 16 controls on a posturography platform. PSP showed excessive force scaling of weight and body motion with high-frequency multiaxial body sway, whereas IPD presented a delayed-onset forward body displacement. Differences in center of mass displacement apparent at very small weights indicate that both syndromes decompensate postural control already within stability limits. PSP may be subject to specific postural system devolution. IPD are susceptible to delayed forward falling. Differential physiotherapy strategies are suggested.Entities:
Keywords: falling; idiopathic Parkinson’s disease; posture; posturography; progressive supranuclear palsy; reafference; self-triggered disturbance
Year: 2018 PMID: 29403423 PMCID: PMC5786748 DOI: 10.3389/fneur.2017.00743
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Clinical parameters of participants in this study: (a) controls subjects (CTR), (b) idiopathic Parkinson’s disease (IPD), and (c) progressive supranuclear palsy (PSP) are shown with sex (0 female, 1 male), age (median ± SD: CTR 60 ± 9.4, IPD 70 ± 7.5, PSP 68 ± 3.6), height in cm, barbell (weight of adjustable instrument, either 0.5 kg or 1 kg), disease duration (YEARS diagnosed with disease in IPD median ± SD 10 ± 4.5 and months in PSP 5 ± 6.4) and clinical scores; Unified Parkinson’s Disease Rating Score (UPDRS) with items I, II, III (median ± SD: IPD 18.5 ± 6.9, PSP 13 ± 3.2) and modified III (scaled each question/task 0–4), PIGD, Hoehn & Yahr Scale (H&Y under optimal medication, median ± SD: IPD 2.5 ± 0.7, PSP 2.5 ± 0.3); for PSP apply specifically: Berg Balance Scale (BBS) (48 ± 0.8), Golbe Score (26 ± 8.3), PSP-staging scale (2 ± 0), the scale of the NNiPPS study (Neuroprotection and Natural History in Parkinson’s Plus Syndromes, 26 ± 5.7), frontal assessment battery (FAB) (14 ± 2.9), Mini-Mental State Examination (MMSE) (29 ± 1.6), PSP rating scale (PSPRS) (30.5 ± 7.5), Schwab & England activities of daily living (SEADL) (80 ± 11), and Montgomery–Åsberg depression rating scale (MADRS) (12 ± 6.7).
| (a) | |||||
|---|---|---|---|---|---|
| Sex | Age | Height | Weight | Barbell | |
| CTR1 | 1 | 60 | 173 | 70 | 1 |
| CTR2 | 0 | 51 | 179 | 73 | 1 |
| CTR3 | 1 | 60 | 163 | 66 | 1 |
| CTR4 | 0 | 60 | 154 | 60 | 1 |
| CTR5 | 0 | 67 | 168 | 64 | 0.5 |
| CTR6 | 1 | 46 | 168 | 105 | 1 |
| CTR7 | 0 | 40 | 167 | 90 | 1 |
| CTR8 | 0 | 73 | 155 | 57 | 1 |
| CTR9 | 0 | 61 | 168 | 57 | 1 |
| CTR10 | 1 | 60 | 174 | 81 | 1 |
| CTR11 | 0 | 56 | 159 | 65 | 1 |
| CTR12 | 1 | 69 | 176 | 100 | 0.5 |
| CTR13 | 0 | 60 | 176 | 81 | 1 |
| CTR14 | 1 | 67 | 180 | 103 | 1 |
| CTR15 | 1 | 42 | 183 | 95 | 1 |
| CTR16 | 1 | 61 | 183 | 115 | 1 |
Whether patients received Rasagiline as participants in the PROSPERA study is marked in the column “Verum” (1 = yes). PSP patients who had Levodopa in their medication regimen are indicated with “1” in the respective column; all IPD patients were given Levodopa as well. In the given collective, there was no significant effect of clinical parameters on performance in vibration effects, nor for Rasagiline within the PSP group.
Figure 1Subjects’ center of foot pressure (COP) depicted for control subjects (black), idiopathic Parkinson’s disease (IPD) (blue), and progressive supranuclear palsy (PSP) (red) with 95% confidence intervals (opaque area of according color) in sagittal (A), lateral (B), and vertical (C) directions. Data of all individuals of one respective group are segmented and averaged 1,000 ms prior to the weight lifting onset and 5,000 ms beyond. An accelerometer inside the weight indicated the course of the fast 90° quarter angle motion (position indicated in (D) at 0-g hanging down; forward 90° holding applies 1-g gravitational pull); (E) depicts weight angular velocity as derivative of (D). Weight lifting onset is at “0.” The peak angular velocity of controls is reached at marker ”a,” the 90° forward position of the weight in controls is reached at marker “b.” Markers “0,” “a” and “b” are depicted continuously throughout (A–E). (F) provides a schematic of the barbell motion for visualization.
Figure 2Subjects’ averaged center of foot pressure (COP) depicted from an on-top viewpoint throughout the weight-lifting cycle with the right arm, from −1 s before lift to +5 s after lifting. Groups are color-coded control subjects (CTR, black), idiopathic Parkinson’s disease (IPD) (blue) and progressive supranuclear palsy (PSP) (red). The circle in each graph depicts the final position of COP at + 5 s, at which the weight was still extended 90° forward.